Diagnostic Histopathology
Volume 14, Issue 4 , Pages 157-163 , April 2008

Recent advances in the diagnosis of renal cell carcinoma

References 

  1. Jemal A, Siegal R, Ward E, Murray T, Xy J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281–291
  3. Patard J, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763–2771
  4. Boer JM, Huber WK, Sultmann H, et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res. 2001;11:1861–1870
  5. Higgins JP, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol. 2003;162:925–932
  6. Furge KA, Lucas KA, Takahashi M, et al. Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res. 2004;64:4117–4121
  7. Srigley JR, Hutter RV, Gelb AB, et al. Current prognostic factors – renal cell carcinoma: Workgroup No. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:992–994
  8. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an Integrated Staging System. J Clin Oncol. 2001;19:1649–1657
  9. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumors. J Pathol. 1997;183:131–133
  10. World Health Organization classification of tumors. In:  Eble N,  Sauter G,  Epstein JI,  Sesterhenn IA editor. Pathology and genetics of tumors of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer Press; 2004;p. 23–37
  11. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumor suppressor gene in renal cell carcinoma. Nat Genet. 1994;7:85–90
  12. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumorigenesis. Genes Chromosomes Cancer. 1998;22:200–209
  13. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal cell carcinoma. Proc Natl Acad Sci U S A. 1994;91:9700–9704
  14. Kibel A, Iliopoulos O, Decaprio JA, Kaelin WG. Binding of the von Hippel-Landau tumor suppressor protein to Elongin B and C. Science. 1995;269:1444–1446
  15. Maxwell PH, Wiesener MS, Chang GW, et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–275
  16. Kovacs G, Fuzesi L, Emanual A, Kung HF. Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer. 1991;3:249–255
  17. Meloni AM, Dobbs RM, Pontes JE, Sandberg AA. Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype. Cancer Genet Cytogenet. 1993;65:1–6
  18. Hernandez-Maarti MJ, Orellana-Alonso C, Paradis-Alos A. Renal adenocarcinoma in an 8-year-old child with a t(X;17) (p11.2;q25). Cancer Genet Cytogenet. 1995;83:82–83
  19. Speicher MR, Schoell B, du Manoir S, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinoma by comparative genomic hybridization. Am J Pathol. 1994;145:356–364
  20. Polascik TJ, Cairns P, Epstein JI, et al. Distal nephron renal tumors: microsatellite allelotype. Cancer Res. 1996;56:1892–1895
  21. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395–2400
  22. Lam JS, Shvarts O, Said JW, et al. Clinicopathological and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer. 2005;103:2517–2525
  23. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655–663
  24. Rioux-Leclercq N, Karakiewicz PI, Trinh QD, et al. Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer. 2007;109:868–874
  25. Ficarra V, Righetti R, Martignoni G, et al. Prognostic value of renal cell carcinoma nuclear grading: multivariate analysis of 333 cases. Urol Int. 2001;67:130–134
  26. Ozer E, Yorukoglu K, Sagol O, Demirel D, Tuzel E, Kirkali Z. Prognostic significance of nuclear morphometry in renal cell carcinoma. BJU Int. 2002;90:20–25
  27. Delahunt B, Sika-Paotonu D, Bethwaite PB, et al. Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. Am J Surg Pathol. 2007;31:957–960
  28. Schullerus D, Herbers J, Chudek J, Kanamaru H, Kovacs G. Loss of heterozygosity at chromosomes 8p, 9p and14q is associated with stage, and grade of non-papillary renal cell carcinomas. J Pathol. 1997;183:151–155
  29. Ljungberg B, Bozoky B, Kovacs G, et al. p53 expression in correlation to clinical outcome in patients with renal cell carcinoma. Scand J Urol Nephrol. 2001;35:15–20
  30. DiSilverio F, Casale P, Colella D, et al. Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma. Cancer. 2000;88:835–843
  31. Kramer BA, Gao X, Davis M, Hall M, Holzbeierlein J, Tawfik O. Prognostic significance of ploidy, MIB-1 proliferation marker and p53 in renal cell carcinoma. J Am Coll Surg. 2005;201:565–570
  32. Tannapfel A, Hahn H, Katalinic A, Fietkau R, Kuhn R, Wittekind CW. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer. 1996;77:164–171
  33. Rioux-Leclercq N, Turlin B, Bansard J, et al. Value of immunohistochemical Ki-67 and p53 determinations are predictive factors of outcome in renal cell carcinoma. Urology. 2000;55:501–505
  34. Gelb AB, Sudilovsky D, Wu CD, Weiss LM, Medeiros LJ. Appraisal of intratumoral microvessel density. MIB-1 score, DNA content and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer. 1997;80:1768–1775
  35. Cheville J, Zincke H, Lohse C, et al. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival. Cancer. 2002;94:2180–2184
  36. Haitel A, Weiner H, Blaschitz U, Marberger M, Susani M. Biologic behavior of and p53 over-expression in multifocal renal cell carcinoma of clear cell type: an immunohistochemical study correlating grading, staging and proliferation markers. Cancer. 1999;65:1593–1598
  37. Uhlman DL, Nguyen PL, Manivel JC, et al. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst. 1994;86:1470–1475
  38. Phuoc NB, Ehara H, Gotoh T, et al. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma. Urology. 2007;69:843–848
  39. Rioux-Leclercq N, Epstein J, Bansard J, et al. Clinical significance of cell proliferation, microvessel density and CD 44 adhesion molecule expression in renal cell carcinoma. Hum Pathol. 2001;32:1209–1215
  40. Tawfik O, Kramer B, Shideler B, Danley M, Kimler BF, Holzbeierlein J. Prognostic significance of CD44, platelet-derived growth factor receptor alpha and cyclooxygenase 2 expression in renal cell carcinoma. Arch Pathol Lab Med. 2007;131:261–267
  41. Sulzbacher I, Birner P, Traxler M, et al. Expression of platelet-derived growth factor alpha receptor is associated with tumor progression in clear cell renal carcinoma. Am J Clin Pathol. 2003;120:107–112
  42. Miyata Y, Koga S, Kanda S, et al. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2 and survival. Clin Cancer Res. 2003;9:1741–1749
  43. Hashimoto Y, Kondo Y, Kimura G, et al. Cyclooxygenase-2 expression and relationship to tumor progression in human renal cell carcinoma. Histopathology. 2004;44:353–359
  44. Biu MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802–811
  45. Atkins M, Regan M, Mier J, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cell cancer. Clin Cancer Res. 2005;11:3714–3721
  46. Djordjevic G, Mozetic V, Mozetic DV, et al. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathol Res Pract. 2007;203:99–106
  47. Nathan P, Chao D, Brock C, et al. The place of VEGF inhibition in the current management of renal cell carcinoma. Br J Cancer. 2006;94:1217–1220
  48. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res. 2007;13:1098–1106
  49. Srinivasan R, Armstrong AJ, Dahut W, George DJ. Anti-angiogenic therapy in renal cell cancer. BJU Int. 2007;99:1296–1300
  50. Maruyama R, Yamana K, Itoi T, et al. Absence of bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma. Br J Cancer. 2006;95:1244–1246
  51. Kausch I, Jiang H, Thode B, Doehn C, Kruger S, Jocham D. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma. Eur Urol. 2005;47:703–709

PII: S1756-2317(08)00031-5

doi: 10.1016/j.mpdhp.2008.02.007

Diagnostic Histopathology
Volume 14, Issue 4 , Pages 157-163 , April 2008

Article Tools

* Image Usage & Resolution